

Programme Schedule

Sunday September 2, 2018

13:30 **Registration**

16:00 **Opening Ceremony**

16:20 **Plenary lecture to be confirmed**

16:50 **Title to be announced**
Prof. Tatjana AVSIC-ZUPANC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

17:20 **Award Ceremony**

17:40 **NAUTA AWARD FOR PHARMACOCHEMISTRY**

18:40 **Synthetic Glycoconjugate Vaccines Against Bacterial Infections Identified Using a Medicinal Chemistry Approach**
Prof. Dr Peter H. SEEBERGER
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)

19:25 **Welcome Reception**

Programme Schedule

Monday September 3, 2018

08:30 **UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY**

09:15 **Sugars and Proteins**
Prof. Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)

10:00 **Exhibition & Coffee**

Session *Session 1 'Technologies'*

Artificial Intelligence Applications in Medicinal Chemistry

- 10:30** **Session Chair**
Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden)
- 10:35** **Artificial Intelligence and its Future**
Dr David E. LEAHY
(THE DISCOVERY BUS LTD, Macclesfield, United Kingdom)
- 11:15** **Scaling De Novo Design - from Single Target to Disease Portfolio**
Dr Willem VAN HOORN
(EXSCIENTIA, Dundee, United Kingdom)
- 11:35** **OC to be selected from submitted abstracts**
- 11:55** **OC to be selected from submitted abstracts**

Session *Session 2 'Chemical Biology'*

Glycans in Medicinal Chemistry: Carbohydrate-Based Vaccines (EuCheMS Session)

- 10:30** **Session Chair**
Dr Sonsoles MARTIN-SANTAMARIA
(BIOLOGICAL RESEARCH CENTER, Madrid, Spain)
- 10:35** **Breaking the Limits in Glycan Recognition by NMR**
Dr JESUS JIMENEZ-BARBERO
(CIC BIOGUNE, Derio, Spain)
- 11:15** **Cancer Vaccines and Biomarkers**
Dr Hans WANDALL
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
- 11:35** **Infectious Diseases. Synthesis and Molecular Recognition**
Dr Laurence MULARD
(INSTITUT PASTEUR, Paris, France)
- 11:45** **OC to be selected from submitted abstracts**

Session *Session 3 'Therapeutic Areas'*

Immuno-Oncology: Novel Therapeutic Opportunities

- 10:30** **Session Chair**
Dr Luc VAN HIJFTE
(SCT & MERCACHEMSYNCOM, Nijmegen, The Netherlands)
- 10:35** **Small Molecule Immune Checkpoint Antagonists for Cancer Therapy**

Programme Schedule

Dr Murali RAMACHANDRA
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India)

11:15 Invited speaker to be confirmed

11:35 OC to be selected from submitted abstracts

11:55 OC to be selected from submitted abstracts

12:15 Exhibition & Lunch

12:15 Company Workshop(s)

Session Session 4 'Technologies'

Timing is Everything: Target Binding Kinetics and Pharmacokinetics

13:15 Session Chair

Prof. Ad P. IJZERMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

13:20 Title to be announced

Prof. Steven CHARLTON
(UNIVERSITY OF NOTTINGHAM, Nottingham, United Kingdom)

14:00 Title to be announced

Dr Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

14:20 Title to be announced

Dr Liesbeth DE LANGE
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

14:40 OC to be selected from submitted abstracts

Session Session 5 'Chemical Biology'

Approaches to Protein Degradation

13:15 Session Chair

Dr Gregory HOLLINGWORTH
(NOVARTIS PHARMA AG, Basel, Switzerland)

13:20 Title to be announced

Dr Mikihiro NAITO
(NATIONAL INSTITUTE OF HEALTH SCIENCES, Tokyo, Japan)

14:00 Title to be announced

Dr Philip CHAMBERLAIN
(CELGENE, Alameda, United States)

14:20 Title to be announced

Dr Nicolas THOMÄ
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

14:40 OC to be selected from submitted abstracts

Session Session 6 'Therapeutic Areas'

Life Science at the Interface of Agro and Pharma

13:15 Session Chair

Programme Schedule

Dr Franz VON NUSSBAUM
(BAYER, Lyon, France)

13:20 A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem

Dr David BERNIER
(BAYER S.A.S. - CROPSCIENCE DIVISION, Lyon, France)

14:00 New Class of Fungicides -New MoA (SDHI)

Dr Joachim RHEINHEIMER
(BASF, Ludwigshafen am Rhein, Germany)

14:20 Title to be announced

Dr Sarah SULZER
(SYNGENTA AG, Basel, Switzerland)

14:40 OC to be selected from submitted abstracts

15:00 Exhibition & Coffee

Session *Session 7*

First Time Disclosures

15:30 Session Chair

Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

15:35 Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy

Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

16:05 Title to be announced

Dr Robert PULZ
(NOVARTIS PHARMA, Basel, Switzerland)

16:35 Discovery of a Novel Oral NO- and Haem-Independent sGC Activator BAY 1101042

Dr Michael G. HAHN
(BAYER HEALTHCARE, Wuppertal, Germany)

17:05 Title to be announced

Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Ingelheim Am Rhein, Germany)

Programme Schedule

17:35 **Poster Session 1 & Networking**

19:30 **End of the Day**

Programme Schedule

Tuesday September 4, 2018

- 08:30 PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
- 09:15 EFMC Prize Ceremony
- 09:20 EFMC Prize for a Young Medicinal Chemist in Industry
- 09:40 EFMC Prize for a Young Medicinal Chemist in Academia
- 10:00 Exhibition & Coffee

Session *Session 8 'Technologies'*

New Chemical Modalities in Medicinal Chemistry

- 10:30 **Session Chair**
Dr Eric VALEUR
(ASTRAZENECA, Västra Frölunda, Sweden)
- 10:35 **New Modalities for Complex and Unprecedented Biological Targets**
Dr Eric VALEUR
(ASTRAZENECA, Västra Frölunda, Sweden)
- 11:15 **Cell Permeability with Beyond 'Rule of 5' Modalities – Do We Understand How This Works?**
Dr Nick TERRETT
(MERCK SHARP & DOHME RESEARCH GMBH (MSD), Kriens, Switzerland)
- 11:35 **Hybrid Macrocycles**
Dr Stephanie GUERET
(ASTRAZENECA R&D, Mölndal, Sweden)
- 11:55 **OC to be selected from submitted abstracts**

Session *Session 9 'Therapeutic Areas'*

Targeting Aggregated Proteins in Neurodegenerative Diseases with Small Molecules

- 10:30 **Session Chair**
Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)
- 10:35 **Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules**
Prof. Markus ZWECKSTETTER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)
- 11:15 **Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha- Synuclein**
Dr Wolfgang WRASIDLO
(UNIVERSITY OF CALIFORNIA SAN DIEGO, La Jolla, United States)
- 11:35 **Title to be announced**
Dr Gergely TOTH
(CANTABIO PHARMACEUTICALS INC., Budapest, Hungary)
- 11:55 **OC to be selected from submitted abstracts**

Programme Schedule

Session Sessions 10 'Chemical Biology'

Targeting the STING Pathway (Stimulator of Interferon Genes)

10:30 Session Chair

Dr Thorsten OOST
(BOEHRINGER INGELHEIM PHARMA GMBH & CO KG, Biberach, Germany)

10:35 Innate Immune Sensing and Signaling of Cytosolic DNA

Dr Zhijian CHEN
(UNIVERSITY OF TEXAS, Dallas, United States)

11:15 Invited speaker to be confirmed

11:35 Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity

Dr Cedric BOULARAN
(INVIVOGEN, Toulouse, France)

11:55 OC to be selected from submitted abstracts

12:15 Exhibition & Lunch

12:15 Company Workshop(s)

Session Flash Poster 1

12 opportunities for young scientists to present a summary of their poster

Session Flash Poster 2

12 opportunities for young scientists to present a summary of their poster

Session Flash Poster 3

12 opportunities for young scientists to present a summary of their poster

Session Session 11 'Technologies'

Expanding Medicinal Chemists' Synthetic Toolbox

13:45 Session Chair

Prof. Gyorgy KESERU
(RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

13:50 Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

Prof. Karl GADEMANN
(UNIVERSITY OF ZURICH, Zurich, Switzerland)

14:30 Stuck in a Rut with Old Chemistry

Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden)

14:50 New Chemical Libraries in Exploration of Chemical Space

Prof. Jurij SVETE
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

15:10 OC to be selected from submitted abstracts

Programme Schedule

Session *Session 12 'Therapeutic Areas'*

Breakthroughs in Polypharmacology Towards Neurological Disorders (ACS Session)

- 13:45 Session Chair**
Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)
- 13:50 Multi-Target and Other Network-Driven Strategies: Emerging Perspectives for Improving the Treatment of Neurological Disorders**
Dr Mark J. MILLAN
(INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France)
- 14:30 Exploiting Kinase Polypharmacology to Promote Nerve Regeneration**
Dr Hassan AL-ALI
(THE MIAMI PROJECT TO CURE PARALYSIS, Miami, United States)
- 14:50 Title to be announced**
Dr Giovanni BOTTEGONI
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)
- 15:10 OC to be selected from submitted abstracts**

Session *Session 13 'Chemical Biology'*

Chemical Biology Approaches to Target Identification

- 13:45 Session Chair**
Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
- 13:50 Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology**
Prof. Hermen OVERKLEEF
(LEIDEN UNIVERSITY, Leiden, The Netherlands)
- 14:30 Title to be announced**
Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France)
- 14:50 Title to be announced**
Dr Alexander ADIBEKIAN
(THE SCRIPPS RESEARCH INSTITUTE, Jupiter, United States)
- 15:10 OC to be selected from submitted abstracts**

- 15:30 Exhibition & Coffee**

Session Flash Poster 4

12 opportunities for young scientists to present a summary of their poster

Session Flash Poster 5

12 opportunities for young scientists to present a summary of their poster

Session Flash Poster 6

12 opportunities for young scientists to present a summary of their poster

- 16:45 Poster Session 2 & Networking**

Programme Schedule

20:00 Concert/Public Event

Programme Schedule

Wednesday September 5, 2018

08:30 Title to be announced
Dr Helga RÜBSAMEN-SCHAEFF
(AICURIS GMBH & CO. KG, Wuppertal, Germany)

09:15 Plenary lecture to be confirmed

10:00 Exhibition & Coffee

Session *Session 14 'Technologies'*

Development of New Synthetic Methodologies for Drug Discovery (CPA Session)

- 10:30 Session Chair**
Dr Ming-Qiang ZHANG
(AMGEN, Shanghai City, China)
- 10:35 Title to be announced**
Dr Jinbo HU
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, China)
- 11:15 Title to be announced**
Dr Zhang-Jie SHI
(FUNDAN UNIVERSITY, Shanghai, China)
- 11:35 Practical Asymmetric Hydrogenation for Making Chiral Drugs**
Prof. Xumu ZHANG
(SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, Guangdong, China)
- 11:55 Ahostry Remviewmetric Aldol Reactions of Heterocyclic Dienolsilanes and α,β -Unsaturated Carbonyl Derived Dienolsilanes**
Prof. Fener CHEN
(FUDAN UNIVERSITY, China)

Session *Session 15 'Therapeutic Areas'*

Upcoming Treatment for NASH and Other Fibrotic Diseases

- 10:30 Session Chair**
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy)
- 10:35 Title to be announced**
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy)
- 11:15 Discovery of LNJ452, a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestasis and NASH**
Dr David TULLY
(NOVARTIS, Emeryville, United States)
- 11:35 OC to be selected from submitted abstracts**
- 11:55 OC to be selected from submitted abstracts**

Session *Session 16 'Chemical Biologies'*

Recent Developments in Kinase Inhibitors

- 10:30 Session chair**
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

Programme Schedule

10:35 EGFR Triple Mutant - Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

11:15 Kinase Case Story
Dr Laurent SCHIO
(SANOFI, Vitry sur Seine, France)

11:35 OC to be selected from submitted abstracts

11:55 OC to be selected from submitted abstracts

12:15 Exhibition & Lunch

12:15 Company Workshop(s)

Session *Session 17*

Emerging topics

13:15 Session Chair to be confirmed

13:20 OC to be selected from submitted abstracts

14:00 OC to be selected from submitted abstracts

14:20 OC to be selected from submitted abstracts

14:40 OC to be selected from submitted abstracts

Session *Session 18 'Therapeutic Areas'*

Addressing Infectious Diseases in the Developing Countries (AFMC Session)

13:15 Session Chair
Dr Renate GRIFFITH
(UNIVERSITY OF NEW SOUTH WALES, UNSW Sydney, Australia)

13:20 All Bugs are Shallow: Open Source Drug Discovery
Prof. Matthew TODD
(UNIVERSITY OF SYDNEY, Sydney, Australia)

14:00 Towards the Development of Small Molecule Therapy for Chikungunya
Prof. Christina CHAI
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

14:20 OC to be selected from submitted abstracts

14:40 OC to be selected from submitted abstracts

Session *Session 19 'Chemical Biology'*

The Spingosine-1-Phosphate Axis: Therapeutic Potential in Inflammation, Cancer, and More (ACS Session)

13:15 Session Chair
Dr Tony LEE
(GILEAD SCIENCES, Seattle, United States)

13:20 Invited speaker to be confirmed

Programme Schedule

- 14:00 Unravelling the Mysteries of the Sphinx: New Therapeutic Targets and Drug Leads from the Phenotypic Screening of Non-Lipid Sphingolipid Mimetics**
Prof. Bernard FLYNN
(MONASH UNIVERSITY, Parkville, Australia)
- 14:20 Active Site Inhibitors of Sphingosine 1-Phosphate Lyase – Exploring Novel Biology With Tool Compounds**
Dr Sven WEILER
(BASILEA PHARMACEUTICA INTERNATIONAL LTD., Basel, Switzerland)
- 14:40 Sphingosine Kinase Drug Discovery and Therapeutic Implications**
Dr Webster L. SANTOS
(VIRGINIA TECH, Blacksburg, United States)
- 15:00 End of the Day**
- 15:30 Excursions**
- 20:00 Banquet**

Programme Schedule

Thursday September 6, 2018

Session Session 20 'Technologies'

Recent Developments in Nucleoside Medicinal Chemistry

- 08:30 Session Chair**
Dr Jared CUMMING
(MSD, Boston, United States)
- 08:35 Cyclic Dinucleotide STING Agonists as Anti-tumor Agents**
Dr Wesley TROTTER
(MSD, Boston, United States)
- 09:15 Invited speaker to be confirmed**
- 09:35 Design and Synthesis of Stable Congeners of Cyclic ADP-Ribose, a Ca²⁺-Mobilizing Second Messenger, Toward Identification of the Target Protein**
Prof. Satoshi SHUTO
(HOKKAIDO UNIVERSITY, Sapporo, Japan)
- 09:55 OC to be selected from submitted abstracts**

Session Session 21 'Therapeutic Areas'

Inflammatory and Autoimmune Diseases

- 08:30 Session Chair**
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
- 08:35 Keynote speaker to be confirmed**
- 09:15 Small-Molecule Immunomodulators of Toll-Like Receptors**
Prof. Hang YIN
(TSINGHUA UNIVERSITY, Beijing, China)
- 09:35 Nonpeptidic Selective Inhibitors of Immunoproteasome**
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
- 09:55 OC to be selected from submitted abstracts**

Session Session 22 'Chemical Biology'

Enzyme Activators and Positive Allosteric Modulators

- 08:30 Session Chair**
Prof. Joachim MITTENDORF
(BAYER AG, Wuppertal, Germany)
- 08:35 Design, Synthesis, and Mechanism of α -Glucocerebrosidase Activators for Gaucher's and Parkinson's Diseases**
Dr Richard B SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)
- 09:15 Allosteric Modulators of the GABA-B Receptor**
Dr Sean C. TURNER
(ABBVIE, Ludwigshafen am Rhein, Germany)
- 09:35 Title to be announced**
Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)
- 09:55 OC to be selected from submitted abstracts**

Programme Schedule

10:15 Exhibition & Coffee (brunch)

Session *Session 23 'Technologies'*

PET Imaging as a Tool in for in Vivo Drug Evaluation and Development (EANM Session)

- 10:45 Session Chair**
Dr Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom)
- 10:50 PET Molecular Imaging Overview**
Dr Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom)
- 11:30 PET for CNS Drug Discovery and Development**
Dr Magnus SCHOU
(KAROLINSKA INSTITUTET, Stockholm, Sweden)
- 11:50 PET for Oncology Drug Discovery and Development**
Prof. Bert WINDHORST
(VRIJE UNIVERSITEIT, AMSTERDAM, The Netherlands)
- 12:10 OC to be selected from submitted abstracts**

Session *Session 24 'Therapeutic Areas'*

Cardiometabolic Diseases

- 10:45 Session Chair**
Dr Soren TULLIN
(NOVO NORDISK A/S, Bagsvaerd, Denmark)
- 10:50 Keynote speaker to be confirmed**
- 11:30 Invited speaker to be confirmed**
- 11:50 GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes**
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
- 12:10 OC to be selected from submitted abstracts**

Session *Session 25*

Recent Highlights

- 10:45 Session Chair to be confirmed**
- 10:50 OC to be selected from submitted abstracts**
- 11:30 OC to be selected from submitted abstracts**
- 11:50 OC to be selected from submitted abstracts**
- 12:10 OC to be selected from submitted abstracts**
- 12:30 Title to be announced**
Prof. Cristina NEVADO
(UNIVERSITY OF ZURICH, Zurich, Switzerland)

Programme Schedule

Chair

13:15 **Closing Remarks, Poster Prizes and Welcome to EFMC-ISMIC 2020**